A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

Inclusion Criteria * Phase 1A: Age greater than or equal to 16 years and less than 40 years (≥16 years, \<40 years). * Phase 1B: Age greater than or equal to 4 years and less than 16 years (≥4 years, \<16 years) * Subjects must be able to sign their own consent for Phase 1A of the study. * Diagnosis of dilated cardiomyopathy (DCM) defined as * Any Congenital Cardiac Malformation with systemic ventricular systolic dysfunction; Idiopathic Cardiomyopathy; Familial/Inherited and/or Genetic Cardiomyopathy; History of Myocarditis; Acquired (Chemotherapy, Iatrogenic, Infection, Rheumatic, Nutritional); Ischemic (e.g. Kawasaki Disease, post-operative); Left ventricular noncompaction; Coronary Artery Disease * Left ventricular ejection fraction less than or equal to 45% documented by two-dimensional echocardiogram or cardiac MRI within the prior six months. * Left ventricular dilation as defined by echocardiography left ventricular and end-diastolic dimension Z score \> +2.0 * Biventricular physiology with systemic left ventricle * Must receive guideline directed heart failure as defined by the American Heart Association, American College of Cardiology, and Heart Failure Society of America 118 * Have been unresponsive or poorly responsive to at least 3 months of maximum guideline directed treatments. Exclusion Criteria * Listed for heart transplantation (as UNOS status 1A) or hospitalized while waiting for transplant (while on inotropes or with ventricular assist device) *…